GlobeImmune Inc (OTCMKTS:GBIM) rose 22.4% during mid-day trading on Friday . The company traded as high as $0.10 and last traded at $0.10, approximately 6,000 shares were traded during mid-day trading. A decline of 59% from the average daily volume of 14,637 shares. The stock had previously closed at $0.08.
The stock’s 50-day moving average price is $0.08 and its 200-day moving average price is $0.11.
About GlobeImmune (OTCMKTS:GBIM)
GlobeImmune, Inc, a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy.
Featured Article: Why do corrections happen?
Receive News & Ratings for GlobeImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune and related companies with MarketBeat.com's FREE daily email newsletter.